The arrival of highly effective obesity pharmacotherapy has reshaped metabolic medicine. This page maps the trials behind weight management, fatty liver, and insulin resistance. Each link opens a concise PICO summary with expert commentary.
Obesity pharmacotherapy
- SCALE — liraglutide 3.0 mg: the trial that opened the era.
- STEP 1 — semaglutide 2.4 mg: 14.9% weight loss.
- SURMOUNT-1 — tirzepatide: up to 20.9% weight loss.
Lifestyle & weight management
- Look AHEAD — the limits of lifestyle for cardiovascular endpoints, and why pharmacotherapy mattered.
MASLD / fatty liver
- Semaglutide + Empagliflozin for NAFLD — combination therapy for liver fat in type 2 diabetes.
Browse every summary
Obesity & Weight Management ·
Metabolic Syndrome & Insulin Resistance ·
MASLD / Fatty Liver ·
Nutrition & Lifestyle
Hormone Insight summaries are reviewed by a practicing endocrinologist and are for healthcare professionals. They summarise published evidence and do not constitute medical advice. See our Editorial Guidelines.